Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

@article{Baldo2015ChimericFP,
  title={Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety},
  author={B. Baldo},
  journal={Drug Safety},
  year={2015},
  volume={38},
  pages={455-479}
}
  • B. Baldo
  • Published 2015
  • Medicine
  • Drug Safety
Chimeric fusion proteins, produced by genetic engineering, are currently made up of effector peptides, for example, a ligand-binding portion of a cytokine or growth factor, extracellular domains of lymphocyte antigens, or a toxin linked to a suitable fusion partner. This review covers eight fusion proteins that have received regulatory approval for human therapy: etanercept, belatacept, abatacept, alefacept, rilonacept, romiplostim, aflibercept, and denileukin-diftitox. Important requirements… Expand
Therapeutic Fc-fusion proteins: Current analytical strategies.
TLDR
This review highlights the wide range of analytical strategies used to fully characterize Fc-fusion proteins and presents also case studies on the structural assessment of all commercially available F c-Fusion proteins, based on the features and critical quality attributes of their ligand binding domains. Expand
Biologics: Monoclonal Antibodies for Non-cancer Therapy, Cytokines, Fusion Proteins, Enzymes, and Hormones
TLDR
Of the 51 different mAbs currently approved and many under development for the management of a variety of non-cancer diseases, mAb development continues to be extended and refined and there is a smaller list of approved cytokines, a number of which, like enzymes used in enzyme replacement therapies, have been developed as orphan drugs. Expand
A New Approach to Drug Therapy: Fc-Fusion Technology
TLDR
Overall, Fc-fusion proteins have proven to be a successful alternative to improve pharmacological properties of therapeutic drugs, with more convenient utilization in the real world and with low immunogenic potential. Expand
The delivery of personalised, precision medicines via synthetic proteins
Introduction: The design of advanced drug delivery systems based on synthetic and su-pramolecular chemistry has been very successful. Liposomal doxorubicin (Caelyx®), and liposomal daunorubicinExpand
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
TLDR
The use of protein fusion technologies such as Fc fusion proteins, fusion to human serum albumin, fused to carboxy-terminal peptide, and other polypeptide fusion approaches to make biobetter drugs with more desirable pharmacokinetic profiles are described. Expand
Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.
  • Y. Qiu, Wei Lv, M. Xu, Yuhong Xu
  • Chemistry, Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2016
TLDR
FnAb-8 and FnAb-12 may be developed into long acting GLP-1R agonists with great potentials in clinical applications and Fn Ab-8 was found to have circulation half-life several folds longer than what have been reported for scFvs. Expand
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics
TLDR
This review focuses on the engineering of biologics, particularly therapeutic antibodies and their application in preclinical development and clinical trials, as well as approved monoclonal antibodies for the treatment of bladder cancer. Expand
The pharmacology and therapeutic applications of monoclonal antibodies
TLDR
Modifications to decrease the immunogenicity and increase the efficacy are described, with examples of optimizing their pharmacokinetic properties and enabling oral bioavailability. Expand
Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products
TLDR
Fusion protein and monoclonal antibody-based tumor necrosis factor (TNF) inhibitors represent established treatment options for a range of inflammatory diseases and there were no IC lots that satisfied the criteria typically applied by the innovator to support comparability with Enbrel®. Expand
Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
TLDR
This study has comprehensively reviewed various components of chimera, such as half-life extension partners and linkers, their shortcomings, and prospective work to be undertaken for developing effective chimeric protein therapeutics. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 230 REFERENCES
Peptibodies: A flexible alternative format to antibodies
TLDR
R Romiplostim, the first peptibody to be approved by the United States Food and Drug Administration and the European Medicines Agency and is indicated for the treatment of immune thrombocytopenic purpura, is being evaluated in Phase 3 clinical testing in combination with chemotherapy in women with ovarian cancer. Expand
Fc fusion as a platform technology: potential for modulating immunogenicity.
TLDR
A review of progress in understanding Fc biology suggests the prospect of engineering products that have an extended half-life and are able to modulate the immune system. Expand
Antibody therapeutics:
  • R. Jefferis
  • Biology, Medicine
  • Expert opinion on biological therapy
  • 2007
TLDR
The present understanding of the molecular interactions between IgG-Fc and effector ligands in vitro has allowed the generation of new antibody structures with altered/improved effector function profiles that may prove optimal for given disease indications. Expand
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
TLDR
A less heralded group of antibody-based therapeutics comprising proteins or peptides fused with an Fc is following the success of classical antibodies. Expand
Introduction: Antibody Structure and Function
TLDR
Characteristics like high neutralizing and recruitment of effector mechanisms, high affinity, and long resident half-life in plasma make the IgG isotype an ideal candidate for generation of therapeutic antibodies. Expand
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
TLDR
How engineering of the FcRn–Fc interaction can generate longer-lasting and more effective therapeutics is discussed, as well as novel Fc-fusion proteins and Fc Rn-dependent delivery approaches in development. Expand
A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity
TLDR
This molecule may prove very useful as a reagent for the antagonism and assay of TNF and lymphotoxin from diverse species in health and disease, and as a means of deciphering the exact mechanism through which TNF interacts with the 55-kD receptor. Expand
Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.
TLDR
The present account reviews the glycosylation patterns observed for the current approved therapeutic antibodies produced in mammalian cell lines, details classical and state-of-the-art analytical methods used for the characterization of glycoforms and discusses the expected benefits of manipulating the carbohydrate components of antibodies by bio- or chemical engineering. Expand
Fc-fusion proteins: new developments and future perspectives
TLDR
Recent results and more generally applicable strategies to improve Fc‐fusion proteins for each application are discussed, with particular attention to the newer, less charted areas. Expand
Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.
TLDR
The results indicate that the efficient delivery of the ADP-ribosyltransferase from DAB486-IL-2 to the cytosol requires the membrane-associating domains of fragment B, which has been postulated to play a role in the diphtherial intoxication of eukaryotic cells. Expand
...
1
2
3
4
5
...